{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:12:49Z","timestamp":1792501969617,"version":"4.5.0"},"reference-count":271,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T00:00:00Z","timestamp":1481846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Chronic kidney disease (CKD) is associated with an enhanced oxidative stress and deep modifications in lipid and lipoprotein metabolism. First, many oxidized lipids accumulate in CKD and were shown to exert toxic effects on cells and tissues. These lipids are known to interfere with many cell functions and to be pro-apoptotic and pro-inflammatory, especially in the cardiovascular system. Some, like F2-isoprostanes, are directly correlated with CKD progression. Their accumulation, added to their noxious effects, rendered their nomination as uremic toxins credible. Similarly, lipoproteins are deeply altered by CKD modifications, either in their metabolism or composition. These impairments lead to impaired effects of HDL on their normal effectors and may strongly participate in accelerated atherosclerosis and failure of statins in end-stage renal disease patients. This review describes the impact of oxidized lipids and other modifications in the natural history of CKD and its complications. Moreover, this review focuses on the modifications of lipoproteins and their impact on the emergence of cardiovascular diseases in CKD as well as the appropriateness of considering them as actual mediators of uremic toxicity.<\/jats:p>","DOI":"10.3390\/toxins8120376","type":"journal-article","created":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T10:55:28Z","timestamp":1481885728000},"page":"376","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":111,"title":["Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins"],"prefix":"10.3390","volume":"8","author":[{"given":"Nans","family":"Florens","sequence":"first","affiliation":[{"name":"CarMeN, INSERM U1060, INRA U1397, INSA de Lyon, Universit\u00e9 Claude Bernard Lyon 1, University of Lyon, F-69621 Villeurbanne, France"},{"name":"Hospices Civils de Lyon, Department of Nephrology, H\u00f4pital E. Herriot, F-69003 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Calzada","sequence":"additional","affiliation":[{"name":"CarMeN, INSERM U1060, INRA U1397, INSA de Lyon, Universit\u00e9 Claude Bernard Lyon 1, University of Lyon, F-69621 Villeurbanne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egor","family":"Lyasko","sequence":"additional","affiliation":[{"name":"CarMeN, INSERM U1060, INRA U1397, INSA de Lyon, Universit\u00e9 Claude Bernard Lyon 1, University of Lyon, F-69621 Villeurbanne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Juillard","sequence":"additional","affiliation":[{"name":"CarMeN, INSERM U1060, INRA U1397, INSA de Lyon, Universit\u00e9 Claude Bernard Lyon 1, University of Lyon, F-69621 Villeurbanne, France"},{"name":"Hospices Civils de Lyon, Department of Nephrology, H\u00f4pital E. Herriot, F-69003 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Soulage","sequence":"additional","affiliation":[{"name":"CarMeN, INSERM U1060, INRA U1397, INSA de Lyon, Universit\u00e9 Claude Bernard Lyon 1, University of Lyon, F-69621 Villeurbanne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2016,12,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2215\/CJN.01930408","article-title":"Accelerated atherosclerotic calcification and Monckeberg\u2019s sclerosis: A continuum of advanced vascular pathology in chronic kidney disease","volume":"3","author":"McCullough","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/CIRCULATIONAHA.106.678342","article-title":"Chronic kidney disease: Effects on the cardiovascular system","volume":"116","author":"Schiffrin","year":"2007","journal-title":"Circulation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1523-1755.2005.00421.x","article-title":"Pathogenesis of vascular calcification in chronic kidney disease","volume":"68","author":"Cozzolino","year":"2005","journal-title":"Kidney Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1161\/01.RES.0000141775.67189.98","article-title":"Pathophysiology of vascular calcification in chronic kidney disease","volume":"95","author":"Moe","year":"2004","journal-title":"Circ. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1053\/j.ackd.2006.01.005","article-title":"Association of kidney function with mortality in patients with chronic kidney disease not yet on dialysis: A historical prospective cohort study","volume":"13","author":"Kovesdy","year":"2006","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1681\/ASN.2004080656","article-title":"Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the atherosclerosis risk in communities study","volume":"16","author":"Muntner","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.ajkd.2006.08.015","article-title":"Oxidative stress is progressively enhanced with advancing stages of CKD","volume":"48","author":"Dounousi","year":"2006","journal-title":"Am. J. Kidney Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1681\/ASN.2011121175","article-title":"Normal and pathologic concentrations of uremic toxins","volume":"23","author":"Duranton","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/ndt\/gfn489","article-title":"Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patients","volume":"24","author":"Cottone","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10157-013-0847-z","article-title":"Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease","volume":"18","author":"Vaziri","year":"2014","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Jardine","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10157-013-0866-9","article-title":"Lipoprotein metabolism and CKD: Overview","volume":"18","author":"Barter","year":"2014","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000321845","article-title":"Lipid disorders and their relevance to outcomes in chronic kidney disease","volume":"31","author":"Vaziri","year":"2011","journal-title":"Blood Purif."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10157-013-0864-y","article-title":"The role of lipids and uremic toxins in cardiovascular disease in CKD","volume":"18","author":"Massy","year":"2014","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrneph.2015.180","article-title":"HDL abnormalities in nephrotic syndrome and chronic kidney disease","volume":"12","author":"Vaziri","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.5551\/jat.12849","article-title":"Lipid Abnormalities in Patients with Chronic Kidney Disease: Implications for the Pathophysiology of Atherosclerosis","volume":"20","author":"Keane","year":"2013","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1681\/ASN.2012080875","article-title":"High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients","volume":"24","author":"Maduell","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial\u2014Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.7326\/0003-4819-138-2-200301210-00010","article-title":"Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency","volume":"138","author":"Tonelli","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/01.ASN.0000068461.45784.2F","article-title":"Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease","volume":"14","author":"Tonelli","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/j.ajkd.2003.09.012","article-title":"The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease","volume":"43","author":"Fathi","year":"2004","journal-title":"Am. J. Kidney Dis."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Palmer, S.C., Navaneethan, S.D., and Craig, J.C. (2013). HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD004289.pub5"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Navaneethan, S.D., Pansini, F., and Perkovic, V. (2009). HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD007784"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Palmer, S.C., Navaneethan, S.D., and Craig, J.C. (2014). HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD005019.pub4"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1523-1755.1999.07101.x","article-title":"Recent advances in statins and the kidney","volume":"56","author":"Oda","year":"1999","journal-title":"Kidney Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1046\/j.1523-1755.2002.00332.x","article-title":"Effect of combining ACE inhibitor and statin in severe experimental nephropathy","volume":"61","author":"Zoja","year":"2002","journal-title":"Kidney Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1172\/JCI116204","article-title":"Lovastatin inhibits proliferation of rat mesangial cells","volume":"91","author":"Kasiske","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.atherosclerosis.2016.06.029","article-title":"LDL-C\/apoB and HDL-C\/apoA-1 ratios predict incident chronic kidney disease in a large apparently healthy cohort","volume":"251","author":"Bae","year":"2016","journal-title":"Atherosclerosis"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM198208053070601","article-title":"Increased lipoprotein-remnant formation in chronic renal failure","volume":"307","author":"Nestel","year":"1982","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"974","DOI":"10.5551\/jat.23309","article-title":"Serum apolipoprotein B-48 concentration is associated with a reduced estimated glomerular filtration rate and increased proteinuria","volume":"21","author":"Okubo","year":"2014","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.atherosclerosis.2007.03.015","article-title":"Remarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal disease","volume":"197","author":"Hayashi","year":"2008","journal-title":"Atherosclerosis"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1016\/j.transproceed.2005.08.062","article-title":"Effect of apolipoprotein B polymorphism in kidney transplantation","volume":"37","author":"Cofan","year":"2005","journal-title":"Transplant. Proc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trsl.2008.11.007","article-title":"Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease","volume":"153","author":"Moradi","year":"2009","journal-title":"Transl. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/ki.1992.238","article-title":"Impaired metabolism of high density lipoprotein in uremic patients","volume":"41","author":"Shoji","year":"1992","journal-title":"Kidney Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1046\/j.1523-1755.2001.00734.x","article-title":"Down-regulation of hepatic lecithin: Cholesterol acyltransferase gene expression in chronic renal failure","volume":"59","author":"Vaziri","year":"2001","journal-title":"Kidney Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/ki.1996.515","article-title":"Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure","volume":"50","author":"Vaziri","year":"1996","journal-title":"Kidney Int."},{"key":"ref_39","first-page":"925","article-title":"Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure","volume":"273","author":"Vaziri","year":"1997","journal-title":"Am. J. Physiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s10157-011-0549-3","article-title":"Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression","volume":"16","author":"Vaziri","year":"2012","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1523-1755.2005.00166.x","article-title":"Down-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure","volume":"67","author":"Kim","year":"2005","journal-title":"Kidney Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-511X-11-111","article-title":"Increase of electronegative-LDL-fraction ratio and IDL-cholesterol in chronic kidney disease patients with hemodialysis treatment","volume":"11","author":"Hirowatari","year":"2012","journal-title":"Lipids Health Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1172\/JCI118657","article-title":"Abnormalities in hepatic lipase in chronic renal failure: Role of excess parathyroid hormone","volume":"97","author":"Klin","year":"1996","journal-title":"J. Clin. Investig."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/ki.1997.263","article-title":"Down-regulation of hepatic lipase expression in experimental nephrotic syndrome","volume":"51","author":"Liang","year":"1997","journal-title":"Kidney Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1046\/j.1523-1755.2003.00281.x","article-title":"Protein restriction and AST-120 improve lipoprotein lipase and VLDL receptor in focal glomerulosclerosis","volume":"64","author":"Sato","year":"2003","journal-title":"Kidney Int."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/ki.1997.263","article-title":"Acquired VLDL receptor deficiency in experimental nephrosis","volume":"51","author":"Liang","year":"1997","journal-title":"Kidney Int."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1046\/j.1523-1755.2003.00281.x","article-title":"Down-regulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis","volume":"64","author":"Sato","year":"2002","journal-title":"Kidney Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1152\/ajprenal.00099.2005","article-title":"Dyslipidemia of chronic renal failure: The nature, mechanisms, and potential consequences","volume":"290","author":"Vaziri","year":"2006","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000182627","article-title":"Mortality risk factors in patients treated by chronic hemodialysis","volume":"31","author":"DeGoulet","year":"1982","journal-title":"Nephron"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0272-6386(12)70364-5","article-title":"Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities","volume":"15","author":"Lowrie","year":"1990","journal-title":"Am. J. Kidney Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jama.291.4.451","article-title":"Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition","volume":"291","author":"Liu","year":"2004","journal-title":"JAMA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/ars.2009.2733","article-title":"Oxidized LDL: Diversity, patterns of recognition, and pathophysiology","volume":"13","author":"Levitan","year":"2010","journal-title":"Antioxid. Redox"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1542-4758.2012.00687.x","article-title":"Oxidized low-density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: Influence of adiponectin and of a polymorphism in the apolipoprotein(a) gene","volume":"16","author":"Ribeiro","year":"2012","journal-title":"Hemodial. Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/0886022X.2011.641515","article-title":"Lipid abnormalities and oxidized LDL in chronic kidney disease patients on hemodialysis and peritoneal dialysis","volume":"34","author":"Samouilidou","year":"2012","journal-title":"Ren. Fail."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000127982","article-title":"Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis","volume":"108","author":"Lobo","year":"2008","journal-title":"Nephron Clin. Pract."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1159\/000112465","article-title":"Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: Acute effects of hemodialysis","volume":"25","author":"Bossola","year":"2007","journal-title":"Blood Purif."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Dro\u017cd\u017c, D., Kwinta, P., Sztefko, K., Kordon, Z., Dro\u017cd\u017c, T., \u0141\u0105tka, M., Miklaszewska, M., Zachwieja, K., Rudzi\u0144ski, A., and Pietrzyk, J.A. (2016). Oxidative stress biomarkers and left ventricular hypertrophy in children with chronic kidney disease. Oxid. Med. Cell. Longev.","DOI":"10.1155\/2016\/7520231"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5414\/CNP58033","article-title":"Oxidized low density lipoprotein (Ox-LDL) as a marker of atherosclerosis in hemodialysis (HD) patients","volume":"58","author":"Takenaka","year":"2002","journal-title":"Clin. Nephrol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.atherosclerosis.2012.07.011","article-title":"Oxidized LDL to autoantibodies against oxLDL ratio\u2014The new biomarker associated with carotid atherosclerosis and cardiovascular complications in dialyzed patients","volume":"224","author":"Pawlak","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.ajkd.2006.03.047","article-title":"Serum myeloperoxidase and mortality in maintenance hemodialysis patients","volume":"48","author":"Brennan","year":"2006","journal-title":"Am. J. Kidney Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/hdi.12049","article-title":"Positive association between plasma levels of oxidized low-density lipoprotein and myeloperoxidase after hemodialysis in patients with diabetic end-stage renal disease","volume":"17","author":"Kitabayashi","year":"2013","journal-title":"Hemodial. Int."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1172\/JCI119379","article-title":"3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima","volume":"99","author":"Hazen","year":"1997","journal-title":"J. Clin. Investig."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/152786","article-title":"LOX-1, OxLDL, and Atherosclerosis","volume":"2013","author":"Pirillo","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0891-5849(01)00697-9","article-title":"Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients","volume":"31","author":"Himmelfarb","year":"2001","journal-title":"Free Radic. Biol. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1172\/JCI5549","article-title":"Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro","volume":"103","author":"Podrez","year":"1999","journal-title":"J. Clin. Investig."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1042\/CS20130369","article-title":"Carbamylation of LDL and its relationship with myeloperoxidase in Type 2 diabetes mellitus","volume":"126","author":"Shiu","year":"2013","journal-title":"Clin. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.freeradbiomed.2004.04.039","article-title":"Thiocyanate catalyzes myeloperoxidase-initiated lipid oxidation in LDL","volume":"37","author":"Exner","year":"2004","journal-title":"Free Radic. Biol. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"878","DOI":"10.5551\/jat.14035","article-title":"Carbamylated-oxidized LDL: Proatherosclerotic effects on endothelial cells and macrophages","volume":"20","author":"Apostolov","year":"2013","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1038\/emm.2014.38","article-title":"CD36, a scavenger receptor implicated in atherosclerosis","volume":"46","author":"Park","year":"2014","journal-title":"Exp. Mol. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1525-1594.2005.29097.x","article-title":"Expression of scavenger receptor CD36 in chronic renal failure patients","volume":"29","author":"Chmielewski","year":"2005","journal-title":"Artif. Organs"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1096\/fj.10-173377","article-title":"Carbamylated low-density lipoprotein induces oxidative stress and accelerated senescence in human endothelial progenitor cells","volume":"25","author":"Carracedo","year":"2011","journal-title":"FASEB J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehu111","article-title":"Carbamylated low-density lipoprotein induces endothelial dysfunction","volume":"35","author":"Speer","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.jacc.2016.07.755","article-title":"Carbamylated low-density lipoproteins induce a prothrombotic state via lox-1: Impact on arterial thrombus formation in vivo","volume":"68","author":"Holy","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ijcard.2010.10.098","article-title":"Carbamylated low-density lipoprotein increases reactive oxygen species (ROS) and apoptosis via lectin-like oxidized LDL receptor (LOX-1) mediated pathway in human umbilical vein endothelial cells","volume":"146","author":"Son","year":"2011","journal-title":"Int. J. Cardiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1681\/ASN.2010040365","article-title":"Chronic Uremia Stimulates LDL Carbamylation and Atherosclerosis","volume":"21","author":"Apostolov","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.jrn.2011.10.023","article-title":"Carbamylated low-density lipoprotein: Nontraditional risk factor for cardiovascular events in patients with chronic kidney disease","volume":"22","author":"Apostolov","year":"2012","journal-title":"J. Ren. Nutr."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1681\/ASN.V52193","article-title":"Uremic serum subfraction inhibits apolipoprotein AI production by a human hepatoma cell line","volume":"5","author":"Kamanna","year":"1994","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/ki.1996.532","article-title":"Effect of serum subfractions from peritoneal dialysis patients on Hep-G2 cell apolipoprotein AI and B metabolism","volume":"50","author":"Shah","year":"1996","journal-title":"Kidney Int."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/01.hco.0000231402.87232.aa","article-title":"Myeloperoxidase: An inflammatory enzyme for generating dysfunctional high density lipoprotein","volume":"21","author":"Shao","year":"2006","journal-title":"Curr. Opin. Cardiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1152\/ajpendo.00364.2001","article-title":"Upregulation of acyl-CoA: Cholesterol acyltransferase in chronic renal failure","volume":"283","author":"Liang","year":"2002","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1681\/ASN.2014030309","article-title":"Dialysis modalities and HDL composition and function","volume":"26","author":"Holzer","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1161\/ATVBAHA.113.303044","article-title":"Effects of native and myeloperoxidase-modified apolipoprotein A-I on reverse cholesterol transport and atherosclerosis in mice","volume":"34","author":"Hewing","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1161\/CIRCRESAHA.114.303454","article-title":"Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase","volume":"114","author":"Shao","year":"2014","journal-title":"Circ. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1089\/ars.2011.4403","article-title":"Myeloperoxidase-derived chlorinating species induce protein carbamylation through decomposition of thiocyanate and urea: Novel pathways generating dysfunctional high-density lipoprotein","volume":"17","author":"Holzer","year":"2012","journal-title":"Antioxid. Redox Signal."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1089\/ars.2010.3640","article-title":"Protein carbamylation renders high-density lipoprotein dysfunctional","volume":"14","author":"Holzer","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"30825","DOI":"10.1074\/jbc.M109.047605","article-title":"Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle","volume":"284","author":"Undurti","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.atherosclerosis.2011.10.038","article-title":"Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients","volume":"220","author":"Honda","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/sj.ki.5002491","article-title":"HDL-inflammatory index correlates with poor outcome in hemodialysis patients","volume":"72","author":"Kopple","year":"2007","journal-title":"Kidney Int."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2010111144","article-title":"Uremia Alters HDL Composition and Function","volume":"22","author":"Holzer","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Mang\u00e9, A., Goux, A., Badiou, S., Patrier, L., Canaud, B., Maudelonde, T., Cristol, J.-P., and Solassol, J. (2012). HDL proteome in hemodialysis patients: A quantitative nanoflow liquid chromatography-tandem mass spectrometry approach. PLoS ONE.","DOI":"10.1371\/journal.pone.0034107"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1681\/ASN.2013111219","article-title":"Restoration of Renal Function Does Not Correct Impairment of Uremic HDL Properties","volume":"26","author":"Kopecky","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.metabol.2014.10.020","article-title":"Dysfunctional high-density lipoproteins in children with chronic kidney disease","volume":"64","author":"Kaseda","year":"2015","journal-title":"Metabolism"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.jacc.2012.09.013","article-title":"Dysfunctional high-density lipoprotein in patients on chronic hemodialysis","volume":"60","author":"Yamamoto","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1681\/ASN.2013111212","article-title":"HDL in children with ckd promotes endothelial dysfunction and an abnormal vascular phenotype","volume":"25","author":"Shroff","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Kopecky, C., Ebtehaj, S., Genser, B., Drechsler, C., Krane, V., Antlanger, M., Kovarik, J.J., Kaltenecker, C.C., Parvizi, M., and Wanner, C. (2016). HDL cholesterol efflux does not predict cardiovascular risk in hemodialysis patients. J. Am. Soc. Nephrol., in press.","DOI":"10.1161\/atvb.36.suppl_1.622"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1161\/01.ATV.0000079011.67194.5A","article-title":"High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors","volume":"23","author":"Kimura","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4103\/1947-2714.103310","article-title":"Antioxidant and anti-inflammatory role of paraoxonase 1: Implication in arteriosclerosis diseases","volume":"4","author":"Litvinov","year":"2012","journal-title":"N. Am. J. Med. Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1681\/ASN.V9112082","article-title":"Decrease of serum paraoxonase activity in chronic renal failure","volume":"9","author":"Dantoine","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Kennedy, D.J., Tang, W.H.W., Fan, Y., Wu, Y., Mann, S., Pepoy, M., and Hazen, S.L. (2013). Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease. J. Am. Heart Assoc.","DOI":"10.1161\/JAHA.113.000104"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s13105-011-0092-4","article-title":"Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease","volume":"67","author":"Kotani","year":"2011","journal-title":"J. Physiol. Biochem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease","volume":"353","author":"Tsimikas","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/j.jacc.2006.03.001","article-title":"Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: Five-year prospective results from the Bruneck study","volume":"47","author":"Tsimikas","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jacc.2012.04.038","article-title":"Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: A rationale for increased efforts to understand its pathophysiology and develop targeted therapies","volume":"60","author":"Tsimikas","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): A randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/ndt\/gfv428","article-title":"Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: Results from the 4D Study","volume":"31","author":"Kollerits","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1194\/jlr.M006742","article-title":"Lipoprotein(a) accelerates atherosclerosis in uremic mice","volume":"51","author":"Pedersen","year":"2010","journal-title":"J. Lipid Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/sj.ki.5002131","article-title":"In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients","volume":"71","author":"Frischmann","year":"2007","journal-title":"Kidney Int."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1525-1594.2000.06483.x","article-title":"Cytokine release and serum lipoprotein (a) alterations during hemodialysis","volume":"24","author":"Tzanatos","year":"2000","journal-title":"Artif. Organs"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.V981474","article-title":"Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome","volume":"9","author":"Reijngoud","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1681\/ASN.V61110","article-title":"Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis","volume":"6","author":"Kronenberg","year":"1995","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10157-013-0875-8","article-title":"Causes and consequences of lipoprotein(a) abnormalities in kidney disease","volume":"18","author":"Kronenberg","year":"2014","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000085290","article-title":"Baseline oxysterols and other markers of oxidative stress, inflammation and malnutrition in the Vitamin E and Intima media thickness Progression in End-stage Renal disease (VIPER) cohort","volume":"100","author":"Boaz","year":"2005","journal-title":"Nephron Clin. Pract."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000091133","article-title":"Oxysterols are increased in plasma of end-stage renal disease patients","volume":"28","author":"Siems","year":"2005","journal-title":"Kidney Blood Press. Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"581","DOI":"10.5301\/JN.2011.6442","article-title":"OxPL\/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients","volume":"24","author":"Bossola","year":"2011","journal-title":"J. Nephrol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000070691","article-title":"Effect of dialysis on plasma total antioxidant capacity and lipid peroxidation products in patients with end-stage renal failure","volume":"21","author":"Samouilidou","year":"2003","journal-title":"Blood Purif."},{"key":"ref_117","first-page":"67","article-title":"Evaluation of oxidant-antioxidant balance in patients on maintenance haemodialysis: A comparative study of dialyzers membranes","volume":"114","author":"Ghais","year":"2010","journal-title":"Nephron Clin. Pract."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/1119-3077.84005","article-title":"Effect of hemodialysis on total antioxidant status of chronic renal failure patients in government hospitals in Lagos Nigeria","volume":"14","author":"Ajala","year":"2011","journal-title":"Niger J. Clin. Pract."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4137\/BMI.S363","article-title":"Serum concentrations of F2-isoprostanes and 4-Hydroxynonenal in hemodialysis patients in relation to inflammation and renal anemia","volume":"3","author":"Wiswedel","year":"2008","journal-title":"Biomark. Insights"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/10715760500445121","article-title":"Vitamin E-coated filter decreases levels of free 4-hydroxyl-2-nonenal during haemodialysis sessions","volume":"40","author":"Odetti","year":"2006","journal-title":"Free Radic. Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.plefa.2006.05.006","article-title":"Hydroxy-alkenals from the peroxidation of n-3 and n-6 fatty acids and urinary metabolites","volume":"75","author":"Guichardant","year":"2006","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1046\/j.1523-1755.2001.0590051960.x","article-title":"Elevated plasma F2-isoprostanes in patients on long-term hemodialysis","volume":"59","author":"Handelman","year":"2001","journal-title":"Kidney Int."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5414\/CNP58190","article-title":"Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients","volume":"58","author":"Ikizler","year":"2002","journal-title":"Clin. Nephrol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1053\/j.jrn.2007.05.011","article-title":"Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients","volume":"17","author":"Himmelfarb","year":"2007","journal-title":"J. Ren. Nutr."},{"key":"ref_125","first-page":"336","article-title":"Antioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal disease","volume":"101","author":"Kamgar","year":"2009","journal-title":"J. Natl. Med. Assoc."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.freeradbiomed.2003.07.003","article-title":"Urinary excretion of three nucleic acid oxidation adducts and isoprostane F(2)alpha measured by liquid chromatography-mass spectrometry in smokers, ex-smokers, and nonsmokers","volume":"35","author":"Harman","year":"2003","journal-title":"Free Radic. Biol. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1006\/abio.1999.4008","article-title":"Quantification of the major urinary metabolite of 15-F2t-isoprostane (8-iso-PGF2\u03b1) by a stable isotope dilution mass spectrometric assay","volume":"269","author":"Morrow","year":"1999","journal-title":"Anal. Biochem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1542-4758.2010.00494.x","article-title":"Biocompatibility of heparin-grafted hemodialysis membranes: Impact on monocyte chemoattractant protein-1 circulating level and oxidative status","volume":"14","author":"Morena","year":"2010","journal-title":"Hemodial. Int."},{"key":"ref_129","first-page":"381","article-title":"Atherosclerosis and oxidative stress","volume":"23","author":"Bonomini","year":"2008","journal-title":"Histol. Histopathol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0891-5849(00)00317-8","article-title":"Mitochondrial free radical generation, oxidative stress, and aging","volume":"29","author":"Cadenas","year":"2000","journal-title":"Free Radic. Biol. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1007\/s00018-002-8520-9","article-title":"The superoxide-generating NADPH oxidase: Structural aspects and activation mechanism","volume":"59","author":"Vignais","year":"2002","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.gastro.2006.05.048","article-title":"NADPH oxidase in the liver: Defensive, offensive, or fibrogenic?","volume":"131","author":"Bataller","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1755-1536-1-5","article-title":"Redox mechanisms in hepatic chronic wound healing and fibrogenesis","volume":"1","author":"Novo","year":"2008","journal-title":"Fibrogenesis Tissue Repair"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.freeradbiomed.2007.03.027","article-title":"Nox enzymes, ROS, and chronic disease: An example of antagonistic pleiotropy","volume":"43","author":"Lambeth","year":"2007","journal-title":"Free Radic. Biol. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jpba.2006.07.030","article-title":"Rapid quantification of malondialdehyde in plasma by high performance liquid chromatography-visible detection","volume":"43","author":"Grotto","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1042\/bst0320139","article-title":"Specific markers of lipid peroxidation issued from n-3 and n-6 fatty acids","volume":"32","author":"Guichardant","year":"2004","journal-title":"Biochem. Soc. Trans."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0891-5849(89)90136-6","article-title":"Biological activities of oxysterols","volume":"7","author":"Smith","year":"1989","journal-title":"Free Radic. Biol. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/35041687","article-title":"Oxidants, oxidative stress and the biology of ageing","volume":"48","author":"Finkel","year":"2000","journal-title":"Nature"},{"key":"ref_139","unstructured":"Peters, T.J. (1996). All about Albumin, Academic Press, Inc."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1042\/bj1710453","article-title":"Lysine residue 240 of human serum albumin is involved in high-affinity binding of bilirubin","volume":"171","author":"Jacobsen","year":"1978","journal-title":"Biochem. J."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0014-5793(93)80353-V","article-title":"Bilirubin attenuates radical-mediated damage to serum albumin","volume":"331","author":"Stocker","year":"1993","journal-title":"FEBS Lett."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"16712","DOI":"10.1016\/S0021-9258(19)89449-8","article-title":"Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation","volume":"269","author":"Stocker","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0167-4838(86)90286-4","article-title":"Antioxidant properties of the proteins caeruloplasmin, albumin and transferrin. A study of their activity in serum and synovial fluid from patients with rheumatoid arthritis","volume":"869","author":"Gutteridge","year":"1986","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/sj.bjp.0707251","article-title":"Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties","volume":"151","author":"Oettl","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1525-139X.2010.00819.x","article-title":"What we know about oxidative stress in patients with chronic kidney disease on dialysis\u2014Clinical effects, potential treatment, and prevention","volume":"24","author":"Locatelli","year":"2011","journal-title":"Semin. Dial."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/1354750X.2012.749302","article-title":"Clinical and research markers of oxidative stress in chronic kidney disease","volume":"18","author":"Tucker","year":"2013","journal-title":"Biomarkers"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1681\/ASN.2006080911","article-title":"Oxidative stress in uremia: The role of anemia correction","volume":"17","author":"Lahera","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/ars.2016.6665","article-title":"Oxidant mechanisms in renal injury and disease","volume":"25","author":"Ratliff","year":"2016","journal-title":"Antioxid. Redox Signal."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1053\/j.jrn.2014.10.010","article-title":"Uremic toxins, oxidative stress, and renal fibrosis: An interwined complex","volume":"25","author":"Chao","year":"2015","journal-title":"J. Ren. Nutr."},{"key":"ref_150","first-page":"165","article-title":"Oxidative stress in chronic kidney disease","volume":"9","author":"Modaresi","year":"2015","journal-title":"Iran. J. Kidney Dis."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3109\/10715762.2013.779373","article-title":"Oxidative stress in patients with cardiovascular disease and chronic renal failure","volume":"47","author":"Popolo","year":"2013","journal-title":"Free Radic. Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.clinbiochem.2011.06.988","article-title":"Oxidative stress and inflammation: Implications in uremia and hemodialysis","volume":"44","author":"Libetta","year":"2011","journal-title":"Clin. Biochem."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.semnephrol.2004.06.026","article-title":"Oxidative stress in uremia: Nature, mechanisms, and potential consequences","volume":"24","author":"Vaziri","year":"2004","journal-title":"Semin. Nephrol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1046\/j.1523-1755.2002.00600.x","article-title":"The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia","volume":"62","author":"Himmelfarb","year":"2002","journal-title":"Kidney Int."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1681\/ASN.2007030355","article-title":"Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD","volume":"19","author":"Ramos","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa013591","article-title":"Endothelial function and oxidative stress in renovascular hypertension","volume":"346","author":"Higashi","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1161\/01.HYP.0000138070.47616.9d","article-title":"Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: What is the clinical significance?","volume":"44","author":"Touyz","year":"2004","journal-title":"Hypertension"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1161\/hy1201.099611","article-title":"Oxidative stress in arterial hypertension: Role of NAD(P)H oxidase","volume":"38","author":"Zalba","year":"2001","journal-title":"Hypertension"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/01.ASN.0000121841.82093.09","article-title":"Increased production of urea hydrogen peroxide from Maillard reaction and a UHP-Fenton pathway related to glycoxidation damage in chronic renal failure","volume":"15","author":"Moh","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000139990","article-title":"Acute exercise may exacerbate oxidative stress response in hemodialysis patients","volume":"109","author":"Fatouros","year":"2008","journal-title":"Nephron Clin. Pract."},{"key":"ref_161","first-page":"435","article-title":"Open comparison study of oxidative stress markers between patients with chronic renal failure in conservative therapy and patients in haemodialysis","volume":"161","author":"Coaccioli","year":"2010","journal-title":"Clin. Ter."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000321508","article-title":"Estimation of oxidative stress markers in chronic kidney disease","volume":"34","author":"Kuchta","year":"2011","journal-title":"Kidney Blood Press. Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/00002480-200109000-00024","article-title":"Do different dialytic techniques have different atherosclerotic and antioxidant activities?","volume":"47","author":"Biasioli","year":"2001","journal-title":"ASAIO J."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000188708","article-title":"Antioxidant enzymes activity in polymorphonuclear leukocytes in chronic renal failure","volume":"71","author":"Mashiach","year":"1995","journal-title":"Nephron"},{"key":"ref_165","first-page":"924","article-title":"Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease","volume":"21","author":"Atamer","year":"2008","journal-title":"J. Nephrol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2362.2005.01488.x","article-title":"Increased glomerular and extracellular malondialdehyde levels in patients and rats with focal segmental glomerulosclerosis","volume":"35","author":"Kuo","year":"2005","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/10715769900300771","article-title":"Antioxidant status and lipid peroxidation in hemodialysis patients undergoing erythropoietin and erythropoietin-vitamin E combined therapy","volume":"31","author":"Inal","year":"1999","journal-title":"Free Radic. Res."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000086079","article-title":"Assessment of oxidative stress in the early posttransplant period: Comparison of cyclosporine A and tacrolimus-based regimens","volume":"25","author":"Vural","year":"2005","journal-title":"Am. J. Nephrol."},{"key":"ref_169","first-page":"791","article-title":"Role of lipid peroxidation, trace elements and anti-oxidant enzymes in chronic renal disease patients","volume":"79","author":"Ongajooth","year":"1996","journal-title":"J. Med. Assoc. Thail."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Romeu, M., Nogues, R., Marcas, L., S\u00e1nchez-Martos, V., Mulero, M., Martinez-Vea, A., Mallol, J., and Giralt, M. (2010). Evaluation of oxidative stress biomarkers in patients with chronic renal failure: A case control study. BMC Res. Notes, 3.","DOI":"10.1186\/1756-0500-3-20"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.jrn.2006.04.008","article-title":"Interrelationship between uremic toxicity and oxidative stress","volume":"16","author":"Rutkowski","year":"2006","journal-title":"J. Ren. Nutr."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/00365590601017170","article-title":"Relationship between uremic toxins and oxidative stress in patients with chronic renal failure","volume":"41","author":"Rutkowski","year":"2007","journal-title":"Scand. J. Urol. Nephrol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"358","DOI":"10.5414\/CNP67358","article-title":"Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients","volume":"67","author":"Ikeda","year":"2007","journal-title":"Clin. Nephrol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1046\/j.1523-1755.2000.00117.x","article-title":"Mechanisms for the formation of glycoxidation products in end-stage renal disease","volume":"57","author":"Weiss","year":"2000","journal-title":"Kidney Int."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1681\/ASN.V1191744","article-title":"Advanced glycation and lipoxidation end products role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism","volume":"11","author":"Miyata","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00726-003-0011-2","article-title":"Free radical-mediated oxidation of free amino acids and amino acid residues in proteins","volume":"25","author":"Stadtman","year":"2003","journal-title":"Amino Acids"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.cardiores.2004.05.001","article-title":"Advanced glycation end products and vascular inflammation: Implications for accelerated atherosclerosis in diabetes","volume":"63","author":"Basta","year":"2004","journal-title":"Cardiovasc. Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"10828","DOI":"10.1074\/jbc.270.18.10828","article-title":"Identification of the major site of Apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor","volume":"270","author":"Bucala","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2337\/diab.44.9.1093","article-title":"Isolation, characterization, and metabolism of the glycated and nonglycated subfractions of low-density lipoproteins isolated from Type I diabetic patients and nondiabetic subjects","volume":"44","author":"Klein","year":"1995","journal-title":"Diabetes"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.bjp.0707395","article-title":"Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors","volume":"153","author":"Coatrieux","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000075533","article-title":"Advanced glycation end products in clinical nephrology","volume":"27","author":"Kalousova","year":"2004","journal-title":"Kidney Blood Press. Res."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1159\/000066956","article-title":"Advanced glycation end products and advanced oxidation protein products in hemodialyzed patients","volume":"20","author":"Kalousova","year":"2003","journal-title":"Blood Purif."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000045934","article-title":"Advanced glycation end products in end-stage renal disease and their removal","volume":"87","author":"Schinzel","year":"2001","journal-title":"Nephron"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000014381","article-title":"Imbalance of oxidants and antioxidants in haemodialysis patients","volume":"17","author":"Canaud","year":"1999","journal-title":"Blood Purif."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/ndt\/gfg074","article-title":"Oxidative stress in end-stage renal disease: An emerging threat to patient outcome","volume":"18","author":"Locatelli","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/ki.2015.166","article-title":"Protein carbamylation and cardiovascular disease","volume":"88","author":"Verbrugge","year":"2015","journal-title":"Kidney Int."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1681\/ASN.2012030254","article-title":"Protein carbamylation predicts mortality in ESRD","volume":"24","author":"Koeth","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Berg, A.H., Drechsler, C., Wenger, J., Buccafusca, R., Hod, T., Kalim, S., Ramma, W., Parikh, S.M., Steen, H., and Friedman, D.J. (2013). Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure. Sci. Transl. Med., 5.","DOI":"10.1126\/scitranslmed.3005218"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1093\/eurheartj\/ehu122","article-title":"Interaction of carbamylated LDL with LOX-1 in the induction of endothelial dysfunction and atherosclerosis","volume":"35","author":"Mehta","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/01.ATV.0000163262.83456.6d","article-title":"Myeloperoxidase and cardiovascular disease","volume":"25","author":"Nicholls","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1523-1755.2003.00139.x","article-title":"Peripheral blood myeloperoxidase activity increases during hemodialysis","volume":"64","author":"Rutgers","year":"2003","journal-title":"Kidney Int."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2215\/CJN.01281005","article-title":"Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients","volume":"1","author":"Stenvinkel","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_193","first-page":"640","article-title":"Myeloperoxidase and progression of aortic valve stenosis in patients undergoing hemodialysis","volume":"22","author":"Wada","year":"2013","journal-title":"J. Heart Valve Dis."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"15521","DOI":"10.1074\/jbc.R700049200","article-title":"Cholesterol, reactive oxygen species, and the formation of biologically active mediators","volume":"283","author":"Murphy","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(98)00196-8","article-title":"Oxysterols and atherosclerosis","volume":"142","author":"Brown","year":"1999","journal-title":"Atherosclerosis"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0021-9150(91)90051-4","article-title":"Cholesterol feeding increases plasma and aortic tissue cholesterol oxide levels in parallel: Further evidence for the role of cholesterol oxidation in atherosclerosis","volume":"89","author":"Hodis","year":"1991","journal-title":"Atherosclerosis"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/10715760100300571","article-title":"Oxysterol profiles of normal human arteries, fatty streaks and advanced lesions","volume":"35","author":"Carpenter","year":"2001","journal-title":"Free Radic. Res."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1161\/01.ATV.19.5.1190","article-title":"Characterization and comparison of the mode of cell death, apoptosis versus necrosis, induced by 7\u03b2-hydroxycholesterol and 7-ketocholesterol in the cells of the vascular wall","volume":"19","author":"Lizard","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1253\/circj.CJ-10-0860","article-title":"Macrophages, oxysterols and atherosclerosis","volume":"74","author":"Shibata","year":"2010","journal-title":"Circulation"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1006\/bbrc.1996.1452","article-title":"Oxysterols induced apoptosis in cultured smooth muscle cells through CPP32 protease activation and bcl-2 protein downregulation","volume":"226","author":"Nishio","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0014-5793(98)01496-3","article-title":"Different patterns of IL-1beta secretion, adhesion molecule expression and apoptosis induction in human endothelial cells treated with 7\u03b1-, 7\u03b2-hydroxycholesterol, or 7-ketocholesterol","volume":"440","author":"Lemaire","year":"1998","journal-title":"FEBS Lett."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s003940050075","article-title":"Oxysterol-induced cell death in U937 and HepG2 cells at reduced and normal serum concentrations","volume":"38","author":"Woods","year":"1999","journal-title":"Eur. J. Nutr."},{"key":"ref_203","first-page":"1625","article-title":"Induction of apoptosis in endothelial cells treated with cholesterol oxides","volume":"148","author":"Lizard","year":"1996","journal-title":"Am. J. Pathol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nature04399","article-title":"Role of cholesterol and lipid organization in disease","volume":"438","author":"Maxfield","year":"2005","journal-title":"Nature"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/cyto.a.20272","article-title":"Multiplexed flow cytometric analyses of pro- and anti-inflammatory cytokines in the culture media of oxysterol-treated human monocytic cells and in the sera of atherosclerotic patients","volume":"69A","author":"Prunet","year":"2006","journal-title":"Cytom. Part A"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10565-005-0141-2","article-title":"Comparison of the cytotoxic, pro-oxidant and pro-inflammatory characteristics of different oxysterols","volume":"21","author":"Prunet","year":"2005","journal-title":"Cell. Biol. Toxicol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0021-9150(01)00563-9","article-title":"Oxysterol-induced activation of macrophage NADPH-oxidase enhances cell-mediated oxidation of LDL in the atherosclerotic apolipoprotein E deficient mouse: Inhibitory role for vitamin E","volume":"160","author":"Rosenblat","year":"2002","journal-title":"Atherosclerosis"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0049-3848(96)00154-5","article-title":"The effect of cholesterol oxidation products on human platelet aggregation","volume":"83","author":"Selley","year":"1996","journal-title":"Thromb. Res."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/07853890410018907","article-title":"Oxysterols and oxysterol binding proteins: Role in lipid metabolism and atherosclerosis","volume":"36","author":"Olkkonen","year":"2009","journal-title":"Ann. Med."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0003-2697(02)00467-0","article-title":"Measurement of oxysterols and alpha-tocopherol in plasma and tissue samples as indices of oxidant stress status","volume":"312","author":"Iuliano","year":"2003","journal-title":"Anal. Biochem."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1089\/ars.2009.2597","article-title":"Generation and biological activities of oxidized phospholipids","volume":"12","author":"Bochkov","year":"2010","journal-title":"Antioxid. Redox Signal."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/0003-9861(91)90224-7","article-title":"Peroxynitrite-induced membrane lipid peroxidation: The cytotoxic potential of superoxide and nitric oxide","volume":"288","author":"Radi","year":"1991","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0891-5849(99)00273-7","article-title":"Pathways of phospholipid oxidation by HOCl in human LDL detected by LC-MS","volume":"28","author":"Jerlich","year":"2000","journal-title":"Free Radic. Biol. Med."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1006\/abbi.1996.0114","article-title":"Peroxidase-mediated bromination of unsaturated fatty acids to form bromohydrins","volume":"327","author":"Carr","year":"1996","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"18351","DOI":"10.1016\/S0021-9258(17)44759-4","article-title":"Oxygenation of biological membranes by the pure reticulocyte lipoxygenase","volume":"265","author":"Kuhn","year":"1990","journal-title":"J. Biol. Chem."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1432-1033.1993.tb17755.x","article-title":"Oxygenation of lipoproteins by mammalian lipoxygenases","volume":"213","author":"Belkner","year":"1993","journal-title":"Eur. J. Biochem."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/S0022-2275(20)31597-2","article-title":"Oxidation of LDL by rabbit and human 15-lipoxygenase: Prevalence of nonenzymatic reactions","volume":"42","author":"Heydeck","year":"2001","journal-title":"J. Lipid Res."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1194\/jlr.R800074-JLR200","article-title":"The role of oxidized phospholipids in atherosclerosis","volume":"50","author":"Berliner","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/01.ATV.0000081215.45714.71","article-title":"Oxidized phospholipid-induced endothelial cell\/monocyte interaction is mediated by a cAMP-dependent R-Ras\/PI3-kinase pathway","volume":"23","author":"Cole","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1161\/01.RES.0000207394.39249.fc","article-title":"Identification of prostaglandin E2 receptor subtype 2 as a receptor activated by OxPAPC","volume":"98","author":"Li","year":"2006","journal-title":"Circ. Res."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1161\/01.RES.80.6.810","article-title":"Induction of P-selectin by oxidized lipoproteins. Separate effects on synthesis and surface expression","volume":"80","author":"Vora","year":"1997","journal-title":"Circ. Res."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.freeradbiomed.2007.10.038","article-title":"Phospholipid chlorohydrin induces leukocyte adhesion to ApoE\u2212\/\u2212 mouse arteries via upregulation of P-selectin","volume":"44","author":"Dever","year":"2008","journal-title":"Free Radic. Biol. Med."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.freeradbiomed.2005.07.013","article-title":"Oxidized-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine induces vascular endothelial superoxide production: Implication of NADPH oxidase","volume":"39","author":"Rouhanizadeh","year":"2005","journal-title":"Free Radic. Biol. Med."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"22925","DOI":"10.1074\/jbc.M002438200","article-title":"Prothrombinase acceleration by oxidatively damaged phospholipids","volume":"275","author":"Weinstein","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1074\/jbc.M005931200","article-title":"Lipid oxidation enhances the function of activated protein C","volume":"276","author":"Safa","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.V99.1.199","article-title":"Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK\/EGR-1 and Ca++\/NFAT","volume":"99","author":"Bochkov","year":"2002","journal-title":"Blood"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2003-04-1127","article-title":"The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: Involvement of P2Y1 and P2Y12 receptors","volume":"103","author":"Erl","year":"2004","journal-title":"Blood"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1537-1891(02)00169-6","article-title":"Activation of vascular cells by PAF-like lipids in oxidized LDL","volume":"38","author":"Marathe","year":"2002","journal-title":"Vascul. Pharmacol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1161\/01.RES.85.4.311","article-title":"Evidence that phospholipid oxidation products and\/or platelet-activating factor play an important role in early atherogenesis: In vitro and In vivo inhibition by WEB 2086","volume":"85","author":"Subbanagounder","year":"1999","journal-title":"Circ. Res."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/biof.5520130106","article-title":"Platelet-activating factor (PAF)-like oxidized phospholipids: Relevance to atherosclerosis","volume":"13","author":"Tokumura","year":"2000","journal-title":"Biofactors"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/MOL.0b013e3282fe1d0e","article-title":"Oxidized phospholipids: Emerging lipid mediators in pathophysiology","volume":"19","author":"Deigner","year":"2008","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"38503","DOI":"10.1074\/jbc.M203318200","article-title":"Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36","volume":"277","author":"Podrez","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"15527","DOI":"10.1074\/jbc.R700054200","article-title":"Oxidized phospholipids as endogenous pattern recognition ligands in innate immunity","volume":"283","author":"Hazen","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/art.20780","article-title":"Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations","volume":"52","author":"Svenungsson","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0027-5107(99)00010-X","article-title":"Lipid peroxidation\u2014DNA damage by malondialdehyde","volume":"424","author":"Marnett","year":"1999","journal-title":"Mutat. Res."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"14247","DOI":"10.1073\/pnas.2332176100","article-title":"Induction of frameshift and base pair substitution mutations by the major DNA adduct of the endogenous carcinogen malondialdehyde","volume":"100","author":"VanderVeen","year":"2003","journal-title":"PNAS"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0891-5849(00)00226-4","article-title":"Role of reactive aldehyde in cardiovascular diseases","volume":"28","author":"Uchida","year":"2000","journal-title":"Free Radic. Biol. Med."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1161\/01.ATV.14.4.605","article-title":"ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum","volume":"14","author":"Palinski","year":"1994","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.numecd.2005.05.003","article-title":"A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress","volume":"15","author":"Stewart","year":"2005","journal-title":"Nutr. Metabol. Cardiovasc. Dis."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1093\/ndt\/gfp102","article-title":"Free and total plasma malondialdehyde in chronic renal insufficiency and in dialysis patients","volume":"24","author":"Bamonti","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/j.ajkd.2005.09.029","article-title":"The determinants of endothelial dysfunction in CKD: Oxidative stress and asymmetric dimethylarginine","volume":"47","author":"Yilmaz","year":"2006","journal-title":"Am. J. Kidney Dis."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000331560","article-title":"Does dialysis modality influence the oxidative stress of uremic patients?","volume":"35","author":"Capusa","year":"2012","journal-title":"Kidney Blood Press. Res."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000193218","article-title":"Nitric oxide metabolites, leukocyte activation markers and oxidative status in dialyzed subjects","volume":"27","author":"Caimi","year":"2009","journal-title":"Blood Purif."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"144","DOI":"10.5414\/CNP68144","article-title":"Oxidative status and prevalent cardiovascular disease in patients with chronic renal failure treated by hemodialysis","volume":"68","author":"Dirican","year":"2007","journal-title":"Clin. Nephrol."},{"key":"ref_245","first-page":"5","article-title":"Does oxidative stress affect the activity of the sodium-proton exchanger?","volume":"56","author":"Bober","year":"2010","journal-title":"Ann. Acad. Med. Stetin."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0891-5849(91)90192-6","article-title":"Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes","volume":"11","author":"Esterbauer","year":"1991","journal-title":"Free Radic. Biol. Med."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.freeradbiomed.2004.06.012","article-title":"Reactions of 4-hydroxynonenal with proteins and cellular targets","volume":"37","author":"Petersen","year":"2004","journal-title":"Free Radic. Biol. Med."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0891-5849(95)02041-1","article-title":"4-Hydroxynonenal inhibits Na(+)-K(+)-ATPase","volume":"20","author":"Siems","year":"1996","journal-title":"Free Radic. Biol. Med."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1074\/jbc.271.11.6033","article-title":"4-Hydroxyhexenal is a potent inducer of the mitochondrial permeability transition","volume":"271","author":"Kristal","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0891-5849(94)90167-8","article-title":"Alterations in mitochondrial membrane fluidity by lipid peroxidation products","volume":"17","author":"Chen","year":"1994","journal-title":"Free Radic. Biol. Med."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/abbi.1995.0036","article-title":"Characterization of Epitopes Recognized by 4-Hydroxy-2-nonenal Specific Antibodies","volume":"324","author":"Uchida","year":"1995","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_252","first-page":"538","article-title":"Modification of low density lipoprotein with 4-hydroxynonenal induces uptake by macrophages","volume":"9","author":"Hoff","year":"1989","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1161\/01.CIR.97.11.1071","article-title":"Induction of Rat Aortic Smooth Muscle Cell Growth by the Lipid Peroxidation Product 4-Hydroxy-2-Nonenal","volume":"97","author":"Ruef","year":"1998","journal-title":"Circulation"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/(SICI)1097-4652(199911)181:2<295::AID-JCP11>3.0.CO;2-I","article-title":"4-Hydroxynonenal induces dysfunction and apoptosis of cultured endothelial cells","volume":"181","author":"Herbst","year":"1999","journal-title":"J. Cell. Physiol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.2353\/ajpath.2007.070218","article-title":"Reactive aldehyde modification of thioredoxin-1 activates early steps of inflammation and cell adhesion","volume":"171","author":"Go","year":"2007","journal-title":"Am. J. Pathol."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000350846","article-title":"Nondialyzable uremic toxins","volume":"35","author":"Piroddi","year":"2013","journal-title":"Blood Purif."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1093\/ndt\/13.10.2583","article-title":"Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients?","volume":"13","author":"Sommerburg","year":"1998","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000094305","article-title":"Elevated levels of Alkanals, alkenals and 4-ho-alkenals in plasma of hemodialysis patients","volume":"26","author":"Alhamdani","year":"2006","journal-title":"Am. J. Nephrol."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1093\/ndt\/gfr386","article-title":"4-Hydroxy-2-hexenal-induced apoptosis in human renal proximal tubular epithelial cells","volume":"26","author":"Bae","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"9383","DOI":"10.1073\/pnas.87.23.9383","article-title":"A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism","volume":"87","author":"Morrow","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0891-5849(99)00264-6","article-title":"Measurement of F2-isoprostanes as an index of oxidative stress in vivo","volume":"28","author":"Roberts","year":"2000","journal-title":"Free Radic. Biol. Med."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.chemphyslip.2003.09.016","article-title":"The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation","volume":"128","author":"Roberts","year":"2004","journal-title":"Chem. Phys. Lipids"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0090-6980(92)90077-7","article-title":"The F2-isoprostane, 8-epi-prostaglandin F2\u03b1, a potent agonist of the vascular thromboxane\/endoperoxide receptor, is a platelet thromboxane\/endoperoxide receptor antagonist","volume":"44","author":"Morrow","year":"1992","journal-title":"Prostaglandins"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1046\/j.1523-1755.1999.00596.x","article-title":"Free-radical-generated F2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cells","volume":"56","author":"Yura","year":"1999","journal-title":"Kidney Int."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1152\/ajpcell.1993.264.6.C1619","article-title":"Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells","volume":"264","author":"Fukunaga","year":"1993","journal-title":"Am. J. Physiol."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1172\/JCI115826","article-title":"Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha, in the rat. Evidence for interaction with thromboxane A2 receptors","volume":"90","author":"Takahashi","year":"1992","journal-title":"J. Clin. Investig."},{"key":"ref_267","first-page":"767","article-title":"Vitamin E ameliorates enhanced renal lipid peroxidation and accumulation of F2-isoprostanes in aging kidneys","volume":"274","author":"Reckelhoff","year":"1998","journal-title":"Am. J. Physiol."},{"key":"ref_268","first-page":"175","article-title":"Oxidative stress, inflammation and cardiovascular disease in chronic renal failure","volume":"21","author":"Cottone","year":"2008","journal-title":"J. Nephrol."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.freeradbiomed.2007.12.026","article-title":"Measurement of F2-isoprostanes, hydroxyeicosatetraenoic products, and oxysterols from a single plasma sample","volume":"44","author":"Lee","year":"2008","journal-title":"Free Radic. Biol. Med."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/j.jrn.2010.06.023","article-title":"Effect of \u03a9-3 fatty acids on plasma level of 8-isoprostane in kidney transplant patients","volume":"21","author":"Ramezani","year":"2011","journal-title":"J. Ren. Nutr."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/01.TP.0000157773.96534.29","article-title":"Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients","volume":"79","author":"Simmons","year":"2005","journal-title":"Transplantation"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/8\/12\/376\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:28:42Z","timestamp":1760210922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/8\/12\/376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,16]]},"references-count":271,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12]]}},"alternative-id":["toxins8120376"],"URL":"https:\/\/doi.org\/10.3390\/toxins8120376","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,16]]}}}